The First Controlled Clinical Trial For A CRISPR Enhanced Bacteriophage Therapy

August 24, 2020

In a recent article published in Clinical Leader, Ed Miseta, Chief Editor highlights Medpace’s partnership with Locus Biosciences and their development of crPhage™, a bacteriophage that have been engineered to deliver the CRISPR-Cas3 constructs into the target bacteria.

Read More